Revenue cycle management: why molecular labs face payment delays

For molecular diagnostics laboratories, the revenue cycle is already exposed to prior authorization requirements, complex medical-necessity rules, unlisted or novel test codes, and payer-specific documentation standards. When those variables are managed after testing, the laboratory is no longer operating a revenue cycle. It is managing a backlog of preventable failures.

The financial effect is direct. First-time denial rates can reach roughly 63% for out-of-network laboratories, compared with approximately 30% to 40% for in-network laboratories. Reimbursement delays may extend to 90 days. Many laboratories carry more than 50 Days in Accounts Receivable while staff repeatedly resubmit claims, request records, correct codes, and negotiate payer responses.

This is the operating reality behind the laboratory revenue cycle management bottlenecks in molecular diagnostics. The problem is not confined to the billing office. It begins with the requisition, specimen intake, ordering provider, payer status, test selection, and documentation captured before the assay is performed.

A claim cannot recover information the laboratory failed to capture at accessioning.

The preanalytical root cause: billing failures begin at specimen intake

Laboratory revenue cycle management starts before a claim exists. It starts when the specimen and requisition enter the organization.

That point is frequently treated as an administrative handoff. It is not. It is the first financial control in the workflow.

A molecular test may be analytically valid and clinically appropriate, yet still produce a delayed or denied claim because the order record lacks one of the inputs required for payment. The missing information may include payer identification, ordering-provider credentials, diagnosis specificity, authorization status, site-of-service details, or documentation supporting medical necessity.

Once the specimen enters production, the laboratory has already committed resources:

• accessioning and specimen processing;
• technologist and pathologist time;
• reagents and consumables;
• instrument capacity;
• quality control and reporting overhead;
• result delivery and clinical support;
• billing and follow-up labor.

If payer requirements are identified only after result release, the laboratory is trying to recover margin after cost has been incurred. That is a poor control model.

The intake record is a revenue instrument

The intake workflow should not treat the requisition as a passive document. It should function as a structured financial and compliance record.

At minimum, the laboratory needs a reliable process for reconciling:

• patient identity and payer information;
• ordering provider and billing provider data;
• diagnosis codes and the clinical indication for testing;
• test name, panel configuration, and applicable CPT coding;
• prior authorization requirements;
• in-network or out-of-network status;
• required clinical notes, pathology reports, or treatment history;
• specimen type, collection details, and chain-of-custody information.

This does not mean every case can be reduced to a simple eligibility check. Molecular testing is not a commodity workflow. A genomic panel, an oncology assay, and a specialized molecular test may carry different payer rules even when they are ordered by the same institution.

The operational requirement is more basic: the laboratory must know which information is missing before it allows the case to proceed without escalation.

A robust intake design therefore assigns a disposition to every case:

1. Ready for testing and billing. The order, payer data, coding inputs, and supporting documentation are sufficient.

2. Pending authorization or documentation. The case is held or routed according to the laboratory’s clinical and operational policy.

3. Exception requiring human review. The test, payer, provider, or coding situation falls outside the standard workflow.

4. Financially exposed. The case may proceed for clinical reasons, but the likely reimbursement risk is visible and recorded.

The objective is not to obstruct patient care. It is to prevent the organization from confusing clinical urgency with administrative completeness.

Specimen chain of custody also affects payment integrity

Chain of custody is usually discussed as a quality and compliance issue. It is also a revenue issue.

A specimen record that cannot be reconciled to the patient, order, collection site, test performed, and final report creates downstream ambiguity. That ambiguity can affect coding, documentation, payer response, and the ability to defend a claim. In a molecular laboratory, the record must support not only what was ordered, but what was actually performed and reported.

Disconnected data creates avoidable work. Staff search across requisitions, email attachments, scanned records, the LIS, payer portals, and billing systems. Each manual reconciliation adds delay and creates another opportunity for transcription error.

The revenue cycle does not begin when a claim is generated in the billing system. It begins when the laboratory establishes a complete, traceable case record.

The financial impact of high denial rates in genomic testing

The 35.3% denial rate associated with billed CPT codes in molecular diagnostics should change how laboratory executives measure performance. A denial is not merely a rejected transaction. It represents the cost of testing, the cost of claim preparation, the cost of follow-up, and the time value of delayed cash.

For a laboratory already operating under staffing pressure, denial volume competes directly with production work. Billing teams spend hours on requests that should have been resolved at intake or coding review. Clinical and administrative staff are pulled into documentation retrieval. Managers monitor aging accounts instead of improving the front-end workflow.

The result is margin compression on several levels:

• Cash conversion slows. Revenue remains trapped in A/R rather than available for payroll, supplies, capital investment, or service expansion.
• Labor cost rises. Each denial may require investigation, payer communication, corrected claims, appeals, and status tracking.
• Capacity is misallocated. Skilled staff perform repetitive recovery work instead of higher-value operational tasks.
• Forecasting becomes unreliable. Gross charges do not translate cleanly into collectible revenue.
• Compliance exposure increases. Repeated manual corrections create opportunities for inconsistent coding and incomplete documentation.

Healthcare organizations may lose an estimated 3% to 5% of net revenue annually to preventable revenue cycle issues, including denials, underpayments, delayed claims, and documentation gaps. For molecular laboratories, the risk is amplified by the complexity of test coverage and the higher denial rate associated with molecular CPT coding.

A laboratory director should not evaluate denial performance only by the number of claims eventually recovered. Recovery can conceal an inefficient system. The more useful question is how much work was required to collect money that should have been paid on the first submission.

Denials must be segmented by operational cause

A single denial percentage is not an operating plan. It is a warning signal.

The laboratory should separate denials into categories that identify where control failed:

This classification changes the conversation. The billing team is no longer asked to “work the denials” as an undifferentiated queue. Each category is assigned to the process owner capable of preventing recurrence.

A prior authorization denial may belong to the ordering workflow. A coding mismatch may belong to the laboratory coding function. A missing pathology report may involve the provider office or medical records team. A payer contract variance may require revenue integrity or contracting review.

The financial owner remains the laboratory. The operational owner may be elsewhere.

Payer complexity: prior authorization and medical necessity

Prior authorization is one of the most consequential bottlenecks in molecular testing. The denial code CO197—prior authorization required—identifies a failure that often occurs before the claim ever reaches adjudication.

The challenge is not simply that authorization exists. The challenge is that authorization may depend on:

• the specific test or panel;
• the diagnosis and disease stage;
• the ordering provider;
• the patient’s benefit plan;
• the laboratory’s network status;
• the site of service;
• the clinical documentation supplied;
• the payer’s interpretation of medical necessity.

An authorization process that records only an approval number is not sufficient control. The laboratory must be able to associate the authorization with the patient, test, payer, ordering provider, date of service, and relevant documentation. If the authorization applies to one test but the laboratory performs another configuration, the claim may still fail.

This is particularly important for novel or unlisted genetic tests. Post-service coverage should not be treated as routine. Without prior authorization and medical-necessity documentation, the laboratory may face a coverage challenge after it has completed the work and released the report.

Build a payer-rule operating layer

Payer rules should not live exclusively in the memory of experienced staff. That model collapses when turnover occurs, volume rises, or a new test is introduced.

A practical payer-rule layer should define:

• which molecular tests require authorization;
• which plans impose special documentation requirements;
• which codes or code combinations create a known risk;
• what information must accompany the authorization request;
• who owns an incomplete case;
• how long the case may remain pending;
• when clinical escalation overrides the standard financial workflow;
• how the final authorization decision is recorded in the LIS or connected system.

The rule set must be maintained. Payer policies change. Test menus change. Coding guidance changes. A static spreadsheet can support a small operation temporarily, but it becomes a control weakness when it is not versioned, audited, and connected to actual workflow decisions.

Medical necessity is an evidence workflow

Medical necessity should not be treated as a paragraph added to an appeal after denial. It is a documentation workflow that begins at ordering.

For molecular testing, the record may need to connect the patient’s diagnosis, treatment history, disease characteristics, and clinical question to the selected test. The laboratory does not always control all of that information. It does control whether missing information is identified, requested, tracked, and attached to the case before billing.

The practical standard is straightforward:

• If the payer requires evidence, the workflow must identify that requirement.
• If the evidence is unavailable, the case must be visible as financially exposed.
• If an exception is approved, the approval must be recorded.
• If the case proceeds without coverage confirmation, the decision must not disappear into an unstructured note.

This is not administrative perfectionism. It is the minimum required to prevent the organization from losing control of its own risk.

Prior authorization is not a clerical step. It is a pre-service revenue decision with a clinical deadline attached.

The LIS and revenue cycle cannot operate as separate islands

Many laboratory workflows remain divided between the LIS, electronic health record, payer portals, document repositories, and billing platforms. The result is a fragmented chain in which the case moves clinically, but the financial data does not move with it.

The exact share of denials caused specifically by inadequate LIS-to-revenue-cycle integration is not established in the available evidence. The operational risk is nevertheless clear. When critical case information is stored in disconnected systems, staff must recreate the relationship manually.

That creates several failure points:

• an authorization number is obtained but not transmitted to billing;
• a corrected diagnosis is present in the clinical record but not in the claim workflow;
• a test is changed after order entry without a corresponding coding review;
• payer status is known by intake staff but not visible to accounts receivable;
• documentation is attached to an appeal but not retained in the central case record;
• a specimen exception is resolved clinically but remains unresolved in the billing queue.

The technology problem is not solved by purchasing another dashboard. The laboratory needs workflow continuity.

Define the minimum data set that must travel with the case

Every molecular case moving from intake to testing, reporting, and billing should carry a consistent set of fields. The exact configuration will vary, but the operating principle is stable: data required for payment must be captured at the earliest practical point and remain traceable through claim submission.

The minimum data set should include:

• patient and subscriber identifiers;
• ordering and referring provider details;
• payer and network status;
• diagnosis and clinical indication;
• test ordered and test performed;
• authorization status and reference information;
• supporting documentation status;
• specimen and collection details;
• coding decision and any exception rationale;
• claim status, denial reason, and corrective action.

The LIS should not be expected to replace a complete revenue cycle platform. It should, however, provide reliable triggers and status information. If a case lacks required documentation or authorization, the system should route it to a defined work queue rather than allow the gap to remain invisible.

The same principle applies to billing. A billing system that receives only a test code and demographic record is being asked to solve a problem too late in the process.

Automation should remove handoffs, not remove accountability

Automation is useful when it eliminates duplicate entry, identifies missing data, applies documented rules, and routes exceptions to the correct owner. It is harmful when it conceals decision logic or creates false confidence.

Laboratory leaders should prioritize automation that supports:

1. Eligibility and payer identification at intake.

2. Authorization prompts linked to the ordered test.

3. Required-document tracking.

4. Code and diagnosis consistency checks.

5. Exception queues with named owners.

6. Claim-status and denial-status feedback into operational reporting.

7. Audit trails for changes to orders, codes, and authorization data.

The objective is not to automate every case. It is to standardize routine cases and make exceptions impossible to miss.

A workflow that moves 95% of cases quickly but leaves the highest-risk cases untracked is not efficient. It is merely fast at creating A/R problems.

Reducing Days in A/R and improving first-pass claim success

Days in A/R exceeding 50 days is a material warning for a molecular laboratory. It indicates that cash is not moving at the expected speed and that payer response cycles are consuming operational capacity.

The response should begin with segmentation. A/R should be organized by the reason cash is delayed, not merely by payer or aging bucket.

A useful management view distinguishes:

• claims awaiting initial payer adjudication;
• claims denied for authorization;
• claims denied as experimental or investigational;
• claims denied as non-covered services;
• claims rejected for coding or demographic errors;
• claims pending documentation;
• claims under appeal;
• claims with suspected underpayment;
• claims with no documented next action.

Every account should have a next action, an owner, and a time threshold. An aging report without those fields is a historical document, not a management tool.

Improve first-pass success through front-end controls

The first-pass claim rate is determined before submission. The laboratory should focus on the controls with the highest operational leverage:

• Validate patient and payer data before accessioning is complete.
• Link the authorization to the exact test and date of service.
• Confirm that the diagnosis supports the ordered service.
• Review unlisted or novel test codes before production where policy permits.
• Make required documentation visible to the ordering and intake teams.
• Reconcile test changes between order entry, laboratory performance, report generation, and billing.
• Confirm that out-of-network cases receive a distinct financial workflow.
• Monitor recurring denial codes by provider, test, payer, and collection site.

Out-of-network laboratories deserve separate attention. First-time denial rates can reach approximately 63% in that setting, compared with 30% to 40% for in-network laboratories. That difference should not be buried in an overall denial average. Network status affects authorization, patient benefits, payer handling, and the likelihood of extended reimbursement delays.

A practical operating framework

Laboratory executives can organize revenue cycle optimization for pathology labs around five control points:

1. Capture

Ensure that the order contains the data required to establish patient identity, payer responsibility, clinical indication, and test definition.

2. Validate

Run eligibility, authorization, documentation, and coding checks before the case reaches the point of no return.

3. Route

Direct standard cases through automated processing. Send exceptions to a defined team with a service-level expectation.

4. Submit

Transmit a claim that matches the test performed, the documentation available, the authorization obtained, and the payer’s requirements.

5. Learn

Use denial and payment data to modify intake rules, payer guidance, coding controls, and staff training. A denial that does not change the upstream workflow is an expense, not an improvement opportunity.

This framework is deliberately operational. It avoids the common mistake of treating denial management as a downstream recovery department. Denial management in molecular testing should produce feedback to accessioning, ordering, coding, utilization management, and system design.

Metrics that belong in the executive review

A laboratory leadership team should review more than gross charges and total A/R. The core dashboard should include:

• first-pass denial rate;
• denial rate by CPT code and test family;
• denial rate by payer and network status;
• percentage of cases missing authorization at intake;
• percentage of cases missing required documentation;
• Days in A/R;
• average age of denied claims;
• appeal overturn rate;
• underpayment rate;
• time from result release to clean claim submission;
• percentage of claims with a documented next action;
• recurring denial categories by operational owner.

These metrics connect compliance, workflow efficiency, and margin. They also expose whether the laboratory is solving causes or merely processing consequences.

A rising appeal overturn rate may appear positive, but it can signal poor first-pass discipline. A falling denial rate with rising pending inventory may mean the laboratory is holding cases before submission rather than improving the workflow. A stable A/R balance may conceal a shift from payer delay to internal backlog.

The numbers must be read together.

The operating mandate

Molecular laboratories cannot protect margin by adding more staff to the back end of a broken process. Additional billing labor may reduce the visible queue, but it will not correct missing authorizations, incomplete requisitions, disconnected systems, or inconsistent test-to-code mapping.

The business case for revenue cycle redesign is already established by the scale of the leakage. A denial rate near 35.3%, first-time out-of-network denial rates near 63%, reimbursement delays of up to 90 days, and Days in A/R above 50 are not isolated billing statistics. They are evidence that clinical production and financial control are operating on separate tracks.

The corrective action is equally clear:

• treat specimen intake as the first revenue cycle checkpoint;
• make authorization and medical necessity visible before testing;
• connect LIS workflow data to billing and denial management;
• segment denials by root cause and assign operational ownership;
• measure first-pass performance, not only eventual recovery;
• use every denial to redesign an upstream control.

Laboratory directors and hospital administrators should assume that preventable revenue leakage will continue until the workflow proves otherwise. If the organization cannot show where authorization, documentation, coding, payer status, and case ownership are recorded, it does not have revenue cycle control. It has a collection process operating after the margin has already been put at risk.